CORRECTION article

Front. Pharmacol., 28 January 2025

Sec. Gastrointestinal and Hepatic Pharmacology

Volume 16 - 2025 | https://doi.org/10.3389/fphar.2025.1478437

Corrigendum: Empagliflozin alleviates hepatic steatosis by activating the AMPK-TET2-autophagy pathway in vivo and in vitro

  • NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China

Article metrics

View details

1

Citations

1,1k

Views

529

Downloads

In the published article, there was an error in Figure 3 as published. The merge of the PA+HG+Empa group (Figure 3D) was presented correctly, but the DAPI of PA + HG + Empa group (Figure 3D) was presented incorrectly. When the authors were preparing the DAPI of PA + HG + Empa group in Figure 3D, they mistakenly copied the image of the DAPI of NC group in Figure 5D. The corrected Figure 3 and its caption appear below.

FIGURE 3

In the published article, there was an error in Figure 4 as published. The authors incorrectly used the image of the PA + HG + Empa group while preparing the image of the PA + HG + AICAR group (Figure 4A). The corrected Figure 4 and its caption appear below.

FIGURE 4

In the published article, there was an error in Supplementary Data Sheet 1. An error was found in the western blot of the β-actin protein panel in Supplementary Figure 5A. The corrected Supplementary Figure 5 can be found in the Supplementary Material link of the original article.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

empagliflozin, autophagy, diabetes, metabolic associated fatty liver disease, lipid accumulation, ten-eleven translocation 2

Citation

Li T, Fang T, Xu L, Liu X, Li X, Xue M, Yu X, Sun B and Chen L (2025) Corrigendum: Empagliflozin alleviates hepatic steatosis by activating the AMPK-TET2-autophagy pathway in vivo and in vitro. Front. Pharmacol. 16:1478437. doi: 10.3389/fphar.2025.1478437

Received

09 August 2024

Accepted

08 January 2025

Published

28 January 2025

Volume

16 - 2025

Edited and reviewed by

Stefano Fiorucci, University of Perugia, Italy

Updates

Copyright

*Correspondence: Liming Chen, ; Bei Sun,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics